The haemophilia treatment landscape has evolved significantly in recent years, with novel approaches such as bispecific antibodies and gene therapy advancing treatment options. Top-level insights from Ipsos’ Haemophilia Therapy Monitor highlight key physician-stated and real-world patient metrics to consider when planning for launch of a new asset or defending an existing asset in this market.
Two comprehensive reports that bring the haemophilia patient voice directly to pharma. Conducted in 2021, Ipsos’ Haemophilia Patient Community provides unique visibility of patients’ unmet needs via an ongoing online panel of those living with the condition. Interactive activities focused on specific elements of their journey, offering insights to support a patient-centric strategy.
Treatment for ATTR-CM and ATTR-PN took a significant step forward with the approval of the first targeted therapies in 2018/2019. With label and access expansions underway, and new MoAs on the horizon, top-level physician-stated and patient-level insights from Ipsos’ ATTR Therapy Monitor provide visibility of the evolving landscapes of these two conditions.
Using data from Ipsos' Sickle Cell Disease Therapy Monitor, this report provides a comprehensive view of current treatment patterns, physician perspectives, and the real-world impact of novel therapies, including Hb F inducers, anti-sickling agents, anti-adhesion therapies and more.
In 2024, the pulmonary arterial hypertension (PAH) landscape experienced significant treatment advancements. Using Ipsos’ PAH Therapy Monitor data captured between 2020 and 2023, we provide a comprehensive view of treatment patterns in the years leading up to these pivotal changes, to inform future strategic endeavours.
2025 marked a pivotal inflection point in HAE treatment, with the approval of two pioneering market entries. Using Ipsos’ HAE Therapy Monitor data, this report provides actionable strategic intelligence essential for optimising new product launches, defending market position, and capitalising on emerging opportunities in this disease landscape.